RHOVAC Stock Overview
RhoVac AB, a pharmaceutical company, develops and commercializes drugs for the treatment of cancer in Sweden and Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RhoVac AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.16 |
| 52 Week High | SEK 38.00 |
| 52 Week Low | SEK 0.47 |
| Beta | 1.17 |
| 11 Month Change | 8.61% |
| 3 Month Change | 96.61% |
| 1 Year Change | -95.72% |
| 33 Year Change | -91.45% |
| 5 Year Change | -92.75% |
| Change since IPO | -91.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| RHOVAC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -17.5% | -8.0% | -2.4% |
| 1Y | -95.7% | 12.6% | 10.9% |
Return vs Industry: RHOVAC underperformed the Swedish Biotechs industry which returned -2.8% over the past year.
Return vs Market: RHOVAC underperformed the Swedish Market which returned 5.8% over the past year.
Price Volatility
| RHOVAC volatility | |
|---|---|
| RHOVAC Average Weekly Movement | 38.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: RHOVAC's share price has been volatile over the past 3 months.
Volatility Over Time: RHOVAC's weekly volatility has increased from 27% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Lars Hedbys | www.rhovac.com |
RhoVac AB, a pharmaceutical company, develops and commercializes drugs for the treatment of cancer in Sweden and Denmark. Its primary product candidate is RV001, an immuno-oncologic drug, which is in phase IIb clinical phase to identify and destroy cells that carry metastatic or metastatic potential cells. The company was founded in 2007 and is headquartered in Lund, Sweden.
RhoVac AB Fundamentals Summary
| RHOVAC fundamental statistics | |
|---|---|
| Market cap | SEK 22.09m |
| Earnings (TTM) | -SEK 50.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs RHOVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHOVAC income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 50.34m |
| Earnings | -SEK 50.33m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 27, 2023
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RHOVAC perform over the long term?
See historical performance and comparison